RT Journal Article
SR Electronic
T1 Cohort Profile: A longitudinal Victorian COVID-19 cohort (COVID PROFILE)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.27.23289157
DO 10.1101/2023.04.27.23289157
A1 Eriksson, Emily M.
A1 Hart, Anne
A1 Forde, Maureen
A1 Foroughi, Siavash
A1 Kiernan-Walker, Nicholas
A1 Mazhari, Ramin
A1 Lucas, Erin C.
A1 Margetts, Mai
A1 Farchione, Anthony
A1 Sheerin, Dylan
A1 Ashdown, George
A1 Evans, Rachel
A1 Chen, Catherine
A1 Ruybal-Pesántez, Shazia
A1 Conway, Eamon
A1 Barrios, Marilou H.
A1 Cornish, Jasper
A1 Edmonds, Maria
A1 Henneken, Lee M.
A1 Ioannidis, Lisa J.
A1 Olechnowicz, Sam W. Z.
A1 Munnings, Ryan B.
A1 Groom, Joanna R.
A1 Hansen, Diana S.
A1 Bowden, Rory
A1 Coussens, Anna K.
A1 Tye-Din, Jason A.
A1 Bryant, Vanessa L.
A1 Mueller, Ivo
YR 2023
UL http://medrxiv.org/content/early/2023/04/29/2023.04.27.23289157.abstract
AB Purpose The COVID PROFILE cohort is a longitudinal clinical study based in Victoria Australia, which was established to understand immunity to SARS-CoV-2 in a low transmission population setting and to identify immunological markers of long-term immunity and immune-dysregulation after both infection and vaccination. Additionally, this cohort was established as a biobank resource for researchers to address other health-related immunological questions.Participants We enrolled 178 adult community members, including household contacts, who had either recovered from a SARS-CoV-2 infection or were SARS-CoV-2 naïve. Only participants ≥18 years of age and, in the case of female participants, non-pregnant women at the time of enrollment were included in the study. Detailed COVID-19 clinical data, vaccination status, medical history and demographics was collected.Findings to date At enrollment, we found that 87.8% of COVID-19 recovered individuals were seropositive with detectable levels of anti-SARS-CoV-2 IgG antibodies. Seronegative COVID-19 recovered individuals included asymptomatic individuals or participants that were enrolled more than 12 months after their COVID-19 diagnosis. Except for one individual who was seropositive at baseline despite a previous SARS-CoV-2 PCR negative diagnosis, all household contacts and other community members enrolled as SARS-CoV-2 PCR negative, were seronegative for all SARS-CoV-2-specific antibodies tested. The infection rate (re-infection or new infection) during 24 months of the study was 42.7%, as determined by either rapid antigen tests, PCRs or serology screens. Of the SARS-CoV-2 recovered participants, 32.6% reported ongoing symptoms at enrollment of which 47% had already experienced ongoing symptoms for more than 12 weeks.Future Plans COVID PROFILE will be used to comprehensively understand temporal immunity to SARS-CoV-2 and COVID-19 vaccines and to understand the impact of host immunological composition on such immunity and symptom severity. Additionally, studies focusing on understanding immunity following breakthrough infections and immunological risk factors that contribute towards development of long COVID are planned.Limitations/Strengths of the studyExtensive clinical information is available and longitudinal samples (blood, saliva and oropharyngeal swabs) collected at regular intervals up to 2.5 years after initial enrolment.This low SARS-CoV-2 transmission population cohort, enables exploration of difference in both the acquisition and maintenance of naturally acquired and vaccine-induced immunity not confounded by prior, frequent and/or undetected exposures.Extensive biobank of numerous blood fractions and biospecimen enables further exploration of mucosal immunity, nasal microbiome and humoral and cellular immunity over time.The cohort may be limited in addressing research questions regarding outcomes and risk factors and their associations where low incidence is expected.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was made possible through Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS. This work was supported by WHO Unity funds (2020/1085469-0) and WEHI Philanthropic funds. The funders had no role in study design, data collection and analysis.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the Walter and Eliza Hall Institute (WEHI) and Melbourne Health Human Research Committees gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors